Skip to main content
SpringerLink
Log in

Chronic myeloproliferative neoplasms

Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017;96:1653–65.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Jentsch-Ullrich K, Eberhardt J, Zeremski V, Koehler M, Wolleschak D, Heidel FH. Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. J Cancer Res Clin Oncol. 2016;142:2041–9.

    Article  CAS  PubMed  Google Scholar 

  4. Mesa R, Verstovsek S, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, et al. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. Eur J Haematol. 2016;97:192–200.

    Article  CAS  PubMed  Google Scholar 

  5. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.

    Article  PubMed  Google Scholar 

  6. Barbui T, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, et al. Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia 2018. (In press)

  7. Kremyanskaya M, Najfeld V, Mascarenhas J, Hoffman R. The polycythemias. In: Hoffman R, editor. Hematology - Basic Principles and Practice. 6th ed: Philadelphia: Elsevier Saunders; 2013. p. 998–1033.

    Chapter  Google Scholar 

  8. Labbe RF, Dewanji A. Iron assessment tests: transferrin receptor vis-a-vis zinc protoporphyrin. Clin Biochem. 2004;37:165–74.

    Article  CAS  PubMed  Google Scholar 

  9. Hastka J, Lasserre JJ, Schwarzbeck A, Hehlmann R. Central role of zinc protoporphyrin in staging iron deficiency. Clin Chem. 1994;40:768–73.

    CAS  PubMed  Google Scholar 

  10. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin II, Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany

    Florian H. Heidel & Andreas Hochhaus

  2. Krukenberg Krebszentrum Halle, Universitätsklinikum Halle, Halle (Saale), Germany

    Haifa-Kathrin Al-Ali

  3. Klinik und Poliklinik für Innere Medizin C, Universitätsklinikum Greifswald, Greifswald, Germany

    Carsten Hirt

  4. Praxis für Hämatologie und Onkologie, Lüdenscheid, Germany

    Dietrich Kämpfe

  5. Gemeinschaftspraxis für Hämatologie und Onkologie, Magdeburg, Germany

    Kathleen Jentsch-Ullrich

  6. Medizinische Klinik III, Universitätsmedizin Rostock, Rostock, Germany

    Christian Junghanss

  7. Klinik für Hämatologie und Onkologie, Palliativmedizin Klinikum Bad Hersfeld, Bad Hersfeld, Germany

    Ralf Nowak

  8. Praxis für Hämatologie und Onkologie, Leipzig, Germany

    Andreas Schwarzer

  9. Hämatologisch-onkologische Gemeinschaftspraxis Halle, Halle, Germany

    Claudia Spohn

  10. Abteilung Hämatologie, Onkologie und Hämostaseologie, Universitätsklinikum Leipzig, Leipzig, Germany

    Vladan Vucinic

  11. Klinik für Hämatologie und Onkologie, Asklepios Klinikum Weissenfels, Weissenfels, Germany

    Thoralf Lange

Authors
  1. Florian H. Heidel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haifa-Kathrin Al-Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carsten Hirt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dietrich Kämpfe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kathleen Jentsch-Ullrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christian Junghanss
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ralf Nowak
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andreas Schwarzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Claudia Spohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Vladan Vucinic
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Andreas Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Thoralf Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

For the Working Party Myeloproliferative Neoplasms of the East German Study Group Hematology/Oncology (OSHO)

Corresponding author

Correspondence to Andreas Hochhaus.

Ethics declarations

Conflict of interest

FHH has served as an advisory board member for Novartis Inc., AH received research support from Novartis, BMS, Incyte and Pfizer. The other authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heidel, F.H., Al-Ali, HK., Hirt, C. et al. Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. Leukemia 32, 2085–2087 (2018). https://doi.org/10.1038/s41375-018-0214-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0214-x

  • Springer Nature Limited

This article is cited by

Search

Navigation